

# **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/EP05/003384

International filing date: 31 March 2005 (31.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0407466.2  
Filing date: 01 April 2004 (01.04.2004)

Date of receipt at the International Bureau: 30 May 2005 (30.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse




The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*William Morrell*

Dated 21 February 2005



**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

02APR04 E885889-2 D00245  
P01/7700 0.00-0407466.2 ACCOUNT CHA

**1/77**

The Patent Office  
Cardiff Road  
Newport  
South Wales NP10 8QQ

1. Your reference

4-33700P1/NFI 8057

2. Patent application number  
(The Patent Office will fill in this part)

**0407466.2**1 APR 2004

3. Full name, address and postcode of the or  
of each applicant  
(underline all surnames)

NOVARTIS AG  
LICHTSTRASSE 35  
4056 BASEL  
SWITZERLAND

Patent ADP number (if you know it)

7125487005

If the applicant is a corporate body, give  
the country/state of its incorporation

SWITZERLAND

4. Title of invention

**Organic Compounds**

5. Name of your agent (If you have one)

**Craig McLean**

"Address for service" in the United  
Kingdom to which all correspondence  
should be sent  
(including the postcode)

**Novartis Pharmaceuticals UK Limited**  
**Patents and Trademarks**  
**Wimblehurst Road**  
**Horsham, West Sussex**  
**RH12 5AB**

Patents ADP number (if you know it)

07181522002

6. If you are declaring priority from one or  
more earlier patent applications, give  
the country and the date of filing of the  
or of each of these earlier applications  
and (if you know it) the or each application  
number

| Country | Priority application number<br>(if you know it) | Date of filing<br>(day/month/year) |
|---------|-------------------------------------------------|------------------------------------|
|---------|-------------------------------------------------|------------------------------------|

7. If this application is divided or otherwise  
derived from an earlier UK  
application, give the number and the  
filing date of the earlier application

| Number of earlier<br>application | Date of filing<br>(day/month/year) |
|----------------------------------|------------------------------------|
|----------------------------------|------------------------------------|

8. Is a statement of inventorship and of  
right to grant of a patent required in  
support of this request? (Answer 'Yes' if:

**Yes**

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.  
(see note (d))

## Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 13

Claim(s) 2

Abstract 1

Drawing(s)

*[Signature]*

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

*/*

Request for preliminary examination and search (*Patents Form 9/77*)

1

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

*Craig McLean*

1<sup>st</sup> April 2004

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs S Schnerr

01403 323069

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) Once you have filled in the form you must remember to sign and date it.
- e) For details of the fee and ways to pay please contact the Patent Office.


DUPLICATE

- 1 -


**Organic Compounds**

The present invention relates to organic compounds, such as lactones, e.g. antiinflammatory lactones.

- 5 In one aspect the present invention provides a compound of formula



such as a compound of formula



wherein R is hydroxy or amino.

10

A compound of formula I includes a compound of formula I'.

Preferably in a compound of formula I

- R is hydroxy;
- R is amino.

15

In another aspect the present invention provides a compound of the present invention which is selected from the group consisting of

Acetic acid 7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfooxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-

- 20 4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester, e.g. including  
 Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfooxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-  
 4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester, and

Acetic acid 7-acetoxy-1-[1-(3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfamoyloxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester, e.g. including

- 5 Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfamoyloxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester.

Compounds provided by the present invention are hereinafter designated as "compound(s) of (according to) the present invention". A compound of formula I includes a compound of formula I'. A compound of the present invention includes a compound in any form, e.g. in free form, in the form of a salt, in the form of a solvate and in the form of a salt and a solvate.

15 In another aspect the present invention provides a compound of the present invention in the form of a salt.

Such salts include preferably pharmaceutically acceptable salts, although pharmaceutically unacceptable salts are included, e.g. for preparation / isolation / purification purposes.


20 A salt of a compound of the present invention includes a metal salt, e.g. or, where appropriate an acid addition salt. Metal salts include for example alkali or earth alkali salts, preferably alkali, such as lithium, potassium, sodium, preferably sodium.

A compound of the present invention in free form may be converted into a corresponding compound in the form of a salt; and vice versa. A compound of the present invention in free form or in the form of a salt and in the form of a solvate may be converted into a 25 corresponding compound in free form or in the form of a salt in non-solvated form; and vice versa.


A compound of the present invention may exist in the form of isomers and mixtures thereof; e.g. optical isomers, diastereoisomers, cis/trans conformers. A compound of the present invention may e.g. contain asymmetric carbon atoms and may thus exist in the form 30 of enantiomers or diastereoisomers and mixtures thereof, e.g. racemates. Any substituent bound to an asymmetric carbon atom may be present in the (R)-, (S)- or (R,S)-configuration, preferably in the (R)- or (S)-configuration. For example, the tetrahydropyranyl ring and the nonadeca-alkenyl chain in a compound of formula I comprises asymmetric C-atoms and substitutents attached to such asymmetric C-atoms, such as sulfonyloxymethyl,

- methylcarbonyloxy, methyl groups, the pyran ring, may be in the (R)- or in the (S)-configuration, e.g. as set out in a compound of formula I' or in the selected group of compounds of the present invention. Additionally a compound of formula I comprises double bonds in the nonadeca-alkenyl chain and substituents bound to such a double bond may be
- 5 cis- or trans-conformers. Preferably the configuration of substituents attached to asymmetric C-atoms of a compound of formula I and the conformers in a compound of formula I are the same as in a compound of formula I, if the starting material for its production, namely a compound of formula II (as set out below) is obtained by fermentation (see production process below).
- 10 Isomeric mixtures may be separated as appropriate, e.g. according, e.g. analogously, to a method as conventional, to obtain pure isomers. The present invention includes a compound of the present invention in any isomeric form and in any isomeric mixture.
- The present invention also includes tautomers of a compound of formula I, where tautomers can exist.

15 In another aspect the present invention provides a process for the production of a compound of formula I comprising sulfating or sulfamoylating a compound of formula



such as a compound of formula



20 and isolating a compound of formula I obtained from the reaction mixture; and, optionally, converting a compound of formula I obtained in another compound of formula I, for example


- converting a compound of formula I obtained into a salt thereof, or,

- 4 -


- if a compound of formula I is obtained in the form of a salt, converting said salt into a free base of a compound of formula I.

A compound of formula II includes a compound of formula II'.

- 5 Sulfation or sulfamoylation may be carried out as appropriate, e.g. according, e.g. analogously, to a process as conventional. In a preferred embodiment of the present invention
  - sulfation is carried out by reaction of a compound of formula II with SO<sub>3</sub>-pyridine complex in organic solvent, e.g. polar organic solvent, such as N,N-dimethylformamide, and isolating a compound of formula I, wherein R is hydroxy from the reaction mixture;
  - sulfamoylation is carried out by treating of a compound of formula II with NaH and further treatment with CISO<sub>2</sub>NH<sub>2</sub> (e.g. obtainable by reaction of chlorosulfonyl isocyanate with formic acid) in organic solvent, e.g. polar organic solvent, such as N,N-dimethylformamide, and isolating a compound of formula I, wherein R is amino, from the reaction mixture.
- 10 15 Salt formation may be carried out as appropriate, e.g. according, e.g. analogously to a method as conventional, e.g. for alkali or earth alkali metal salt formation a compound of formula I may be treated with a base of formula MET-OH or of formula MET'OH<sub>2</sub>, wherein MET is an alkali ion and MET' is an earth alkali ion.
- 20 In another aspect the present invention provides a compound of formula II, e.g. useful as an intermediate in the production of a compound of the present invention, e.g. in free base form or in the form of a salt, including salts as described above for a compound of the present invention.
- 25 A compound of formula II is herein designated also as "an intermediate of (according to) the present invention" in distinction to a compound of formula I "a compound of (according to) the present invention".  
A compound of formula II may be obtained as appropriate, e.g. according, e.g. analogously, to a process as conventional, e.g. or as described herein.
- 30 In another aspect the present invention provides a process for the preparation of a compound of formula II, comprising acylating a compound of formula



such as of formula



- 5 A compound of formula III includes a compound of formula III'.
- 
- Acylation may be carried out as appropriate, e.g. according, e.g. analogously, to a method as conventional. In a preferred embodiment of the present invention acylation is carried out by reaction of a compound of formula II with acetic acid anhydride in organic solvent, e.g. pyridine, and isolating a compound of formula II obtained from the reaction mixture.
- 10 Optionally, and if desired, salt formation of a compound of formula II may be carried out as appropriate, e.g. as described above for a compound of formula I.

A compound of formula III may be obtained as appropriate, e.g. according, e.g. analogously, to a process as conventional, e.g. e.g. by culturing a strain producing a compound of formula III, e.g. a strain of the genus *Microsphaeropsis* Hohn, such as the fungus strain NRRL 15684, in the presence of a culture medium and recovering a compound of formula III from the culture medium, e.g. by chromatography, see e.g. US4753959.

In an intermediate of formula II or in a compound of formula III (starting materials), functional groups, if present, optionally may be in protected form or in the form of a salt, if a salt-forming group is present. Protecting groups, optionally present, may be removed at an appropriate stage, e.g. according, e.g. analogously, to a method as conventional.

Any compound described herein may be prepared as appropriate, e.g. according, e.g. analogously, to a method as conventional, e.g. or as specified herein.

The compounds of the present invention, e.g. including a compound of formula I and of formula I', exhibit pharmacological activity and are therefore useful as pharmaceuticals. In particular we have found surprisingly that the compounds of the present invention show anti-inflammatory activity and are e.g. useful in diseases associated with inflammation.

5

Antiinflammatory activity may be tested in test systems *in vivo*, namely in the IL-8 induced leucocytes emigration model, in the Topical ICD-TPA mouse model and in the ACD mouse model, e.g. as described below, wherein the following abbreviations are used:

- ACD allergic contact dermatitis  
10 DAE mixture of acetylacetamide, ethanol and acetone  
ICD isocitric dehydrogenase  
PBS phosphate buffered saline  
TPA 12-O-tetradecanoyl phorbol-13-acetate (phorbol-12-myristate)

Test compounds include compounds of the present invention, such as

- 15 Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfooxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester; and  
Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfamoyloxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester.  
20 Reference substances include heparan sulfate and anti-IL-8 antibodies.

## TEST SYSTEMS

### 1. IL-8 induced leucocytes emigration model

- 25 Comprise 24 to 36 female Balb/c mice, 18 - 20 g; IL-8 control group; reference group; buffer control group and 3 to 6 test groups. Human recombinant IL-8 is injected at 1 µg in 100 µl PBS i.p..

- 5 mg of a test compound, or reference compound, respectively, is dissolved in 1 ml of PBS. Immediately after i.p. injection of IL-8 100 µl of the test compound-solution are injected i.v. (= 30 500 µg/mouse). 4 hours after IL-8 injection the mice are anaesthetized and blood is collected by orbital puncture. The mice are sacrificed and peritoneal exudate cells harvested as follows: 5 ml of PBS are injected i.p. and after 1 minute as much of it as possible is recovered. Total cell counts of blood and peritoneal cells are performed on the Toa-Counter (Coulter).

The cytopsin preparation is done on the Shandon Cytocentrifuge "Cytospin" 2. The blood smears and cytopsin preparations are stained with Hemacolor (Merck). Differential cell counts of blood smears and peritoneal cells are performed under the microscope. Statistical evaluation (t-test) of the results is performed.

- 5 In the IL-8 induced leucocytes emigration model compounds of the present invention induce significantly (up to 90%), dose-dependant inhibition of the neutrophil emigration (comparable to the reference compound heparan sulfate and anti-IL-8 antibodies).

2. Topical ICD-TPA mouse model (TPA-induced irritant contact dermatitis)

- 10 10 µl of a 0.01% TPA solution is epicutaneously applied to the inner surface of the right ear of 8 NMRI mice per group for elicitation of an inflammatory pinnal swelling. The test animals are treated topically with 10 µl of a test compound (dissolved in DAE) 30 minutes before the application of TPA; control animals are treated similarly with the vehicle DAE alone. Six hours after TPA-treatment the animals are sacrificed, both ear lobes cut off at the basis  
15 and weighed. Difference in auricular weights are taken as a measure of inflammatory swelling [right (treated, irritated) vs left (untreated, non irritated) ears, in %].  
In the topical ICD-TPA model the compounds of examples 1 and 2 inhibit inflammation by ca. 30% to ca. 70% when applied at 10 mM to 30 mM in volumes of 10 µl.

20 3. Topical ACD-model (oxazolone-sensitized mice)

- 10 10 µl of 2% oxazolone is epicutaneously applied to the inner surface of the right ear of 8 NMRI mice per group which mice are sensitized against oxazolone. After 30 minutes the test animals are treated topically with 10 µl of a test compound (dissolved in DAE). Twenty four hours later the animals are sacrificed. Inflammatory swelling is measured as set out under point "2. Topical ICD-TPA mouse model" above.  
25 In the topical ACD-model the compounds of examples 1 and 2 inhibit inflammation by ca. 30% when applied at 30 mM in volumes of 10 µl.

- 30 The compounds of the present invention show therapeutic activity and are thus useful in the treatment of diseases associated with inflammation, e.g. for use as antiinflammatory agents, e.g. for use in the treatment of inflammatory disorders, such as in suppression of neoplastic diseases, e.g. inflammatory skin diseases and autoimmune diseases, such as: psoriasis, atopical dermatitis, contact dermatitis and related eczematous dermatitises, seborrheic dermatitis, atopic dermatitis, phototoxic and photoallergic dermatitis, Lichen planus,

Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus, Alopecia areata and acne.

- 5 In another aspect the present invention provides a compound of the present invention for use as a pharmaceutical, e.g. for the treatment of diseases associated with inflammation.

For pharmaceutical use a compound of the present invention includes one or more, preferably one, compounds of the present invention, e.g. a combination of two or more 10 compounds of the present invention.

In another aspect the present invention provides the use of a compound of the present invention for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of diseases associated with inflammation.

15

The compounds of Examples 1 and 2 are preferred compounds of the present invention.

The compounds of the invention may be administered in similar manner to known standards for use in the treatment of diseases associated with inflammation.

- 20 In a further aspect the present invention provides a method of treatment of diseases which are associated with inflammation, which method comprises administering to a subject in need of such treatment an effective amount, e.g. an antiinflammatory effective amount of a compound of the present invention; e.g. in the form of a pharmaceutical composition.

- 25 Treatment includes treatment and prophylaxis.

For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the chemical nature and the pharmakokinetic data of a compound of the present invention employed, the individual host, the mode of administration and the nature and severity of the conditions being treated. However, in general, for satisfactory results in larger 30 mammals, for example humans, an indicated daily dosage is in the range from about 5 mg to about 1500 mg (ca. 0.06 mg/kg to ca. 20 mg/kg body weight), such as about 50 to about 1200 mg (ca. 4 mg/kg to ca. 15 mg/kg body weight) of a compound of the present invention; conveniently administered, for example, in divided doses up to four times a day.

A compound of the present invention may be administered by any conventional route, for

example enterally, e.g. including nasal, buccal, rectal, oral, administration; parenterally, e.g. including intravenous, intramuscular, subcutaneous administration; or topically; e.g. including epicutaneous, intranasal, intratracheal administration;

- 5 e.g. in form of coated or uncoated tablets, capsules, (injectable) solutions, solid solutions, suspensions, dispersions, solid dispersions; e.g. in the form of ampoules, vials, in the form of creams, gels, pastes, inhaler powder, foams, tinctures, lip sticks, drops, sprays, suppositories.

The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt, e.g. metal salt; or in free form; optionally in the form of a solvate. The compounds of the present invention in the form of a salt exhibit the same order of activity as the compounds of the present invention in free form; optionally in the form of a solvate.

15 A compound of the present invention may be used for pharmaceutical treatment according to the present invention alone, or in combination with one or more other pharmaceutically active agents. Such other pharmaceutically active agents include e.g. other pharmaceutically active compounds which are active in the treatment of diseases associated with inflammation, e.g. and antibacterials.

20 Combinations include fixed combinations, in which two or more pharmaceutically active agents are in the same formulation; kits, in which two or more pharmaceutically active agents in separate formulations are sold in the same package, e.g. with instruction for co-administration; and free combinations in which the pharmaceutically active agents are packaged separately, but instruction for simultaneous or sequential administration are given.

25 In another aspect the present invention provides a pharmaceutical composition comprising a compound of the present invention in association with at least one pharmaceutical excipient, e.g. appropriate carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners, lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, 30 wetting agents and/or emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers.

In another aspect the present invention provides a pharmaceutical composition according to the present invention, further comprising another pharmaceutically active agent.

- 10 -

- Such compositions may be manufactured according, e.g. analogously to a method as conventional, e.g. by mixing, granulating, coating, dissolving or lyophilizing processes. Unit dosage forms may contain, for example, from about 50 mg to about 1000 mg, such as 100  
5 mg to about 500 mg.

In the following Examples all temperatures are in degrees Celsius ( $^{\circ}\text{C}$ ) and are uncorrected.

The following abbreviations are used:

- 10 DMF N,N-dimethylformamide

**Example 1 Compound 286-253**

**Acetic acid 7-acetoxy-1-[1-(3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfooxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester**

- 5    1A. Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-6-hydroxymethyl-2'-oxo-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester
- 10    5 g of (2R,3S,4R,6R)-6'-((3E,5E,11E,13E)-2,8-Dihydroxy-1,1,5,7,9,13,15,17-octamethyl-nonadeca-3,5,11,13-tetraenyl)-3,4,4'-trihydroxy-6-hydroxymethyl-3,4,5,6-tetrahydro-2.H.-[2,3']bipyranyl-2'-one, dissolved in 25 ml of pyridine and 25 ml of acetic anhydride, are stirred for 18 hours, solvent is evaporated, the evaporation residue obtained is dissolved in toluene and pyridinium salts are filtered off. From the filtrate obtained solvent is evaporated and the evaporation residue obtained is dissolved in 100 ml of methanol. To the mixture obtained 4 ml of 33% aqueous NH<sub>3</sub> are added, the mixture obtained is stirred for 18 hours, solvent is evaporated and the evaporation residue is subjected to chromatography.
- 15    Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-6-hydroxymethyl-2'-oxo-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester is obtained.
- 20    <sup>1</sup>H-NMR (CDCl<sub>3</sub> / CD<sub>3</sub>OD 4:1) 6.30 (d, 1H, H<sub>3</sub>, J = 15 Hz); 6.20 (d, 1H, H<sub>11</sub>, J = 15.5 Hz); 5.91 (s, 1H, H<sub>5</sub>); 5.37-5.58 (m, 4H, H<sub>1,2,5,10</sub>); 5.08-5.20 (m, 3H, H<sub>3-pyranly,4-pyranly,13</sub>); 4.82 (d, 1H, H<sub>2-pyranly</sub>, J = 9.4 Hz); 4.75 (dd, 1H, H-7, J = 4.4,7.8 Hz); 3.70-3.85 (m, 2H, H<sub>a-acetoxymethyl</sub>, H<sub>b-acetoxymethy</sub>); 3.61 (m, 1H, H<sub>6-pyranly</sub>); 2.88 (m, 1H, H-6); 2.58 (m, 1H, H-14); 2.24 (m, 1H, H<sub>-5a-pyranly</sub>); 2.20 (m, 1H, H<sub>9a</sub>); 2.08 (s, 3H, COCH<sub>3</sub>), 2.04 (s, 3H, COCH<sub>3</sub>); 2.01 (s, 3H, COCH<sub>3</sub>), 2.00 (s, 3H, COCH<sub>3</sub>); 1.83 (m, 1H, H<sub>9b</sub>); 1.73-1.77 (m, 2H, H<sub>5b-pyranly</sub>, H<sub>8</sub>); 1.73 (2xs, 6H, CH<sub>3-4,12</sub>); 1.17-1.30 (m, 3H, H<sub>15a,16,17a</sub>); 1.24 (s, 3H, gem-CH<sub>3</sub>); 1.21 (s, 3H, gem-CH<sub>3</sub>); 1.05-1.18 (m, 2H, H<sub>15b,17b</sub>); 0.98 (d, 3H, CH<sub>3-6</sub>, J = 7 Hz); 0.93 (d, 3H, CH<sub>3-14</sub>, J = 7 Hz); 0.80-0.88 (m, 9H, CH<sub>3-8,16,18</sub>); MS-ESI m/e 829 (MH<sup>+</sup>, 100).

- 30    1B. Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfooxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester

953 mg of SO<sub>3</sub>-pyridine complex are added to 1g of acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-6-hydroxymethyl-2'-oxo-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-

- 12 -

2,4,10,12-tetraenyl ester in 90 ml of DMF and the resulting solution is stirred for 12 hours. From the mixture obtained solvent is evaporated and the evaporation residue obtained is subjected to chromatography.

Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-

5 oxo-6-sulfooxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester is obtained.

<sup>1</sup>H-NMR (CDCl<sub>3</sub> / CD<sub>3</sub>OD 4:1, 330K) 6.28 (d, 1H, H<sub>3</sub>, J = 15.5 Hz); 6.03 (d, 1H, H<sub>11</sub>, J = 15.4 Hz); 5.75 (s, 1H, H<sub>5</sub>); 5.56 (d, 1H, H<sub>1</sub>, J = 7.6 Hz); 5.50 (d, 1H, H<sub>5</sub>, J = 7.5 Hz); 5.44-5.48 (m, 3H, H<sub>3-pyranyl,2,10</sub>); 5.14 (m, 1H, H<sub>4-pyranyl</sub>); 5.12 (d, 1H, H<sub>13</sub>, J = 9.6 Hz); 4.87 (d, 1H, H<sub>2-pyranyl</sub>, J = 11.1 Hz); 4.77 (dd, 1H, H<sub>7</sub>, J = 5.3,6.9 Hz); ABX-system ( $\square_A$  = 4.37, H<sub>a-acetoxymethyl</sub>,  $\square_B$  = 4.08, H<sub>b-acetoxymethyl</sub>,  $\square_X$  = 4.02, H<sub>6-pyranyl</sub>, J<sub>AB</sub> = 10.9, J<sub>AX</sub> = 3.0, J<sub>BX</sub> = 1.9 Hz); 2.89 (m, 1H, H<sub>6</sub>); 2.55 (m, 1H, H<sub>14</sub>); 2.24 (m, 1H, H<sub>9a</sub>); 2.20 (m, 1H, H<sub>5a-pyranyl</sub>); 2.12 (m, 1H, H<sub>5b-pyranyl</sub>); 2.05 (s, 3H, COCH<sub>3</sub>), 2.02 (2xs, 6H, COCH<sub>3</sub>); 1.90 (m, 1H, H<sub>9b</sub>); 1.87 (s, 3H, COCH<sub>3</sub>); 1.80 (m, 1H, H<sub>8</sub>); 1.72 (2xs, 6H, CH<sub>3-4,12</sub>); 1.22-1.30 (m, 3H, H<sub>15a, 16, 17a</sub>); 1.23 (s, 3H, gem-CH<sub>3</sub>); 1.18 (s, 3H, gem-CH<sub>3</sub>); 1.13 (m, 1H, H<sub>17b</sub>); 1.08 (m, 1H, H<sub>15b</sub>); 0.95 (d, 3H, CH<sub>3-6</sub>, J = 6.9 Hz); 0.93 (d, 3H, CH<sub>3-15</sub>, J = 6.7 Hz); 0.82-0.87 (m, 9H, CH<sub>3-8,16,18</sub>); MS-ESI m/e 947 (MK<sup>+</sup>, 100).

### Example 2 Compound 286-808

Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfamoyloxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester

36 mg of NaH are added to 600 mg of acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-6-hydroxymethyl-2'-oxo-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-

24,10,12-tetraenyl ester in 18 ml of DMF and the mixture obtained is stirred for 45 minutes. To the mixture obtained 432 mg of CISO<sub>2</sub>NH<sub>2</sub> are added and the resulting solution is stirred for further 2 hours. From the mixture obtained solvent is evaporated, the evaporation residue is treated with ethyl acetate and the organic layer obtained is extracted with saturated sodium bicarbonate and brine. The organic layer obtained is dried, solvent is evaporated and the evaporation residue is subjected to chromatography.


Acetic acid (2E,4E,10E,12E)-7-acetoxy-1-[1-((2R,3R,4R,6R)-3,4-diacetoxy-4'-hydroxy-2'-oxo-6-sulfamoyloxymethyl-3,4,5,6-tetrahydro-2.H.,2'.H.-[2,3']bipyranyl-6'-yl)-1-methyl-ethyl]-4,6,8,12,14,16-hexamethyl-octadeca-2,4,10,12-tetraenyl ester is obtained.

- 13 -

<sup>1</sup>H-NMR (CDCl<sub>3</sub> / CD<sub>3</sub>OD 4:1) 6.26 (d, 1H, H<sub>3</sub>, J = 15.5 Hz); 6.03 (d, 1H, H<sub>11</sub>, J = 15.5 Hz); 5.77 (s, 1H, H<sub>5'</sub>); 5.74 (m, 1H, H<sub>3-pyranyl</sub>) 5.57 (d, 1H, H<sub>1</sub>, J = 7.5 Hz); 5.43-5.50 (m, 2H, H<sub>2,10</sub>); 5.47 (d, 1H, H<sub>5</sub>, J = 7.8 Hz ); 5.10 (d, 1H, H<sub>13</sub>, J = 9.3 Hz); 5.09 (m, 1H, H<sub>4-pyranyl</sub>); 4.80 (m, 1H, H<sub>2-pyranyl</sub>); 4.76 (dd, 1H, H<sub>7</sub>, J = 4.6,7.6 Hz); ABX-system ( $\Delta_A$  = 4.37, H<sub>a-acetoxymethyl</sub>,  $\Delta_B$  = 1H, H<sub>b-pyranyl</sub>); 4.20, H<sub>b-acetoxymethyl</sub>,  $\Delta_X$  = 3.90, H<sub>6-pyranyl</sub>, J<sub>AB</sub> = 11.9, J<sub>AX</sub> = 2.5, J<sub>BX</sub> = 4.6 Hz); 2.90 (m, 1H, H<sub>6</sub>); 2.58 (m, 1H, H<sub>14</sub>); 2.23 (m, 1H, H<sub>9a</sub>); 2.14 (m, 1H, H<sub>5a-pyranyl</sub>); 2.07 (s, 3H, COCH<sub>3</sub>), 2.03 (s, 3H, COCH<sub>3</sub>); 2.02 (s, 3H, COCH<sub>3</sub>); 1.93 (m, 1H, H<sub>5b-pyranyl</sub>); 1.89 (s, 3H, COCH<sub>3</sub>); 1.87 (m, 1H, H<sub>9b</sub>); 1.79 (m, 1H, H<sub>8</sub>); 1.74 (2xs, 6H, CH<sub>3-4,12</sub>); 1.22-1.32 (m, 3H, H<sub>15a, 16, 17a</sub>); 1.23 (s, 3H, gem-CH<sub>3</sub>); 1.19 (s, 3H, gem-CH<sub>3</sub>); 1.13 (m, 1H, H<sub>17b</sub>); 1.08 (m, 1H, H<sub>15b</sub>); 0.96 (d, 3H, CH<sub>3-6</sub>, J = 7 Hz); 0.93 (d, 3H, CH<sub>3-15</sub>, J = 6.9 Hz); 0.82-0.87 ( m, 9H, CH<sub>3-8,16,18</sub>); MS-ESI *m/e* 908 (MH<sup>+</sup>, 50).

**Patent Claims**

1. A compound of formula



5

wherein R is hydroxy or amino.

2. A compound of claim 1 wherein R is hydroxy.

- 10 3. A compound of claim 1, wherein R is amino.

4. A compound of any one of claims 1 to 3 in the form of a salt.

5. A compound of claim 4 in the form of an alkali salt.

15

6. A compound of claim 5, which is a sodium salt.

7. A compound of claim 6 wherein R is amino.

- 20 8. A compound of any one of claims 1 to 7 for use as a pharmaceutical.

9. A pharmaceutical composition comprising a compound of any one of claims 1 to 7 beside at least one pharmaceutically acceptable excipient.

- 25 10. Use of a compound of any one of claims 1 to 7 for the manufacture of a medicament, for the treatment of diseases associated with inflammation.

- 15 -

11. A method of treatment of diseases which treatment comprises administering to a subject in need of such treatment an effective amount of a compound of any one of claims 1 to 7, e.g. in the form of a pharmaceutical composition according to claim 9.

5 SC/3/25/2004 11:19 PM

**Abstract**

Lactones, which are pharmaceutically active in diseases associated with inflammation.



